Evidence for granulocyte-mediated macrophage activation after C. parvum immunization.
It has been previously demonstrated that at the peak of the peritoneal response to Corynebacterium parvum (Day 4), cytolytic macrophages can be characterized by the presence of intracellular bacteria. In the present study, the role of neutrophils in the activation of peritoneal macrophages by C. parvum was investigated. Inflammatory neutrophils isolated 5 hr after ip administration of C. parvum were transferred to normal, syngeneic mice and the peritoneal macrophages of recipients harvested 4 days later were tested for cytoxicity against HeLa cells. Neutrophils isolated from mice 5 hr after C. parvum immunization were effective in inducing cytolytic macrophages. Less than 100-fold as much bacteria was needed to induce comparable levels of cytotoxic activity when introduced inside granulocytes. Neutrophils obtained from mice 48 hr after C. parvum injection or mononuclear cells were not good macrophage activators. Viable neutrophils were not required as freeze-thawed cells were able to activate macrophages in recipient mice. The intracellular distribution of C. parvum changed dramatically with time. Initially almost all bacteria were found within neutrophils. By 24 hr, many macrophages contained either bacteria or granulocytes which had ingested C. parvum. Pyridine extracts of C. parvum, which do not activate peritoneal macrophages when injected directly into mice, did not induce neutrophils capable of activating macrophages. The residue of pyridine-extracted C. parvum did induce neutrophils that could activate macrophages when transferred. The results suggest that processing of the bacteria by inflammatory granulocytes may be an obligatory step in macrophage activation by this agent. The peak response occurred earlier than T-cell immunity is usually observed and it is suggested that direct activation of macrophages via ingestion of neutrophils may represent the earliest stage of macrophage activation by C. parvum.
D000818:Animals; D000942:Antigens, Bacterial / Q000008:administration & dosage*; D001202:Ascitic Fluid / Q000166:cytology; D003602:Cytotoxicity, Immunologic; D007111:Immunity, Cellular; D007114:Immunization; D007249:Inflammation / Q000276:immunology / Q000382:microbiology; D008262:Macrophage Activation; D051379:Mice; D008805:Mice, Inbred A; D008810:Mice, Inbred C57BL; D009504:Neutrophils / Q000276:immunology* / Q000637:transplantation; D010587:Phagocytosis; D011425:Propionibacterium acnes / Q000187:drug effects / Q000276:immunology; D011725:Pyridines / Q000494:pharmacology
D000942:Antigens, Bacterial; D011725:Pyridines; C023666:pyridine